The introduction of high-efficacy therapies for relapsing-remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous interferon beta-1a demonstrated significantly reduced annualized relapse rates and improved magnetic resonance imaging outcomes, and were significantly more likely to achieve no evidence of disease activity and reduction in brain volume loss. In two of the studies, alemtuzumab-treated patients had a significantly reduced risk of 6-month confirmed disease worsening, compared with subcutaneous interferon beta-1a. Benefits were maintained throughout 5 years, with a majority of patients receiving no alemtuzumab retreatment or other disease-modifying therapy. Trial results support alemtuzumab's manageable, consistent safety profile in relapsing-remitting multiple sclerosis. Infusion-associated reactions, the most frequent adverse events (AEs), can be minimized by corticosteroid pretreatment, monitoring, and symptomatic management. Other AEs include infections and autoimmune events. Oral anti-herpes prophylaxis should be initiated on the first day of each alemtuzumab treatment course and continued according to local guidelines. Overall cancer risk was lower in the alemtuzumab clinical trials than in a reference population; however, continuing surveillance will determine if alemtuzumab may be associated with certain malignancies such as thyroid papillary carcinoma and melanoma, which are currently identified as potential risks. The post-approval risk management strategy includes a safety monitoring program. Autoimmune AEs (thyroid events, immune thrombocytopenia, nephropathies) can be detected in a timely manner with the monitoring program, which includes physician and patient education about the signs and symptoms, monthly renal and hematologic monitoring, and quarterly thyroid function monitoring for 48 months after the last alemtuzumab course. Education, vigilance by physicians and patients, and monthly laboratory monitoring are recommended to maintain alemtuzumab's positive benefit:risk profile.

Department of Neurology 2nd Faculty of Medicine Charles University Motol University Hospital Prague Czech Republic

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Neurological Institute Cleveland Clinic Cleveland OH USA

See more in PubMed

Giovannoni G, Arnold D, Cohen J, et al. Long-term responders from the CARE-MS I study: no evidence of disease activity for 4 years following 2 courses of alemtuzumab and no further treatment. Neurology. 2016;86(16 suppl):3, 054.

Hauser SL, Bar-Or A, Comi C, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234. PubMed

Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015;4(5):460–469. PubMed

University of California, San Francisco MS-EPIC Team. Cree BA, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499–510. PubMed PMC

Giovannoni G, Cook C, Rammohan K, CLARITY study group et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–337. PubMed

Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–260. PubMed

Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152–158. PubMed

Stangel M, Penner I, Kallmann B, Lukas C, Kieseier BC. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8(1):3–13. PubMed PMC

Beer S, Khan F, Kesselring J. Rehabilitation interventions in multiple sclerosis: an overview. J Neurol. 2012;259(9):1994–2008. PubMed

Tomassini V, Matthews PM, Thompson AJ, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012;8(11):635–646. PubMed PMC

Cohen JA, Coles AJ, Arnold DL, CARE-MS I investigators et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–1828. PubMed

Coles AJ, Twyman CL, Arnold DL, CARE-MS II investigators et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. PubMed

Giovannoni G, Gold R, Kappos L, et al. Delayed-release dimethyl fumarate and disability assessed by the multiple sclerosis functional composite: integrated analysis of DEFINE and CONFIRM. Mult Scler J Exp Transl Clin. 2016;2 2055217316634111. PubMed PMC

Prosperini L, Barletta V, De Giglio L, Fanelli F, Borriello G, Pozzilli C. A five-year clinical follow-up study of patients with multiple sclerosis who started natalizumab. Neurology. 2014;82(10 suppl):7, 215.

Coles A, Arnold DL, Cohen JA, et al. Patients with active RRMS and an inadequate response to prior therapy demonstrate durable improvements in relapse and disability following treatment with alemtuzumab: 5-year follow-up of the CARE-MS II study. Neurology. 2016;86(16 suppl):3, 022.

Giovannoni G, Cohen JA, Coles AJ, CARE-MS II Investigators et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016;87(19):1985–1992. PubMed PMC

Biogen Inc . TYSABRI (natalizumab). Prescribing Information. Cambridge, MA: Biogen Idec; 2013.

Lemtrada (alemtuzumab) Summary of Product Characteristics. 2016. [Accessed March 29, 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf.

Lemtrada . (Alemtuzumab) Prescribing Information. Cambridge, MA: Genzyme Corporation; 2016.

Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31(9):1028–1035. PubMed

Lisotti A, Azzaroli F, Brillanti S, Mazzella G. Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis. 2012;44(4):356–357. PubMed

Polman CH, O’Connor PW, Havrdova E, AFFIRM Investigators et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. PubMed

Subei AM, Ontaneda D. Risk mitigation strategies for adverse reactions associated with the disease-modifying drugs in multiple sclerosis. CNS Drugs. 2015;29(9):759–771. PubMed PMC

Filippi M, Rocca MA, Barkhof F, Attendees of the Correlation between Pathological MRI findings in MS workshop et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012;11(4):349–360. PubMed

Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014;122(3):15–58. PubMed

Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528–1532. PubMed

Multiple Sclerosis Therapy Consensus Group (MSTCG) Wiendl H, Toyka KV, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449–1463. PubMed

Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007;259(1–2):104–108. PubMed

Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006;38(3):167–171. PubMed

Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225. PubMed PMC

Havrdova E, Arnold DL, Cohen JA, CARE-MS I and CAMMS03409 Investigators et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107–1116. PubMed PMC

Coles AJ, Cohen JA, Fox EJ, CARE-MS II and CAMMS03409 Investigators et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89(11):1117–1126. PubMed PMC

Coles AJ, Boyko AN, Cohen JA, et al. Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I) (P213). Paper presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 14–17, 2016; London, UK.

Fox EJ, Alroughani R, Brassat D, et al. Efficacy of alemtuzumab is durable over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy in the absence of continuous treatment (CARE-MS II) (P1150). Paper presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 14–17, 2016; London, UK.

Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord. doi: 10.1177/1756285617722706. Prepublished August 4, 2017. PubMed DOI PMC

CAMMS223 Trial Investigators. Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–1801. PubMed

Kovarova I, Arnold DL, Cohen JA, et al. Alemtuzumab pharmacokinetics and pharmacodynamics in Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (P341). Paper presented at: European Neurological Society; June 9–12, 2012; Prague, Czech Republic.

Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KHG. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162(1):1–11. PubMed PMC

Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191(12):5867–5874. PubMed

Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008;4(7):384–398. PubMed

Cross AH, Waubant E. MS and the B cell controversy. Biochim Biophys Acta. 2011;1812(2):231–238. PubMed

Kasper LH, Arnold DL, Cohen JA, et al. Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS II study. Mult Scler. 2013;19(11 suppl):P531.

Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2010;10(12):1789–1797. PubMed

Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013;4(4):1000152. PubMed PMC

Turner MJ, Lamorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol. 2013;261(1–2):29–36. PubMed

Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(Pt 8):2232–2247. PubMed

Dombrowski Y, O’Hagan T, Dittmer M, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20(5):674–680. PubMed PMC

Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7. PubMed PMC

Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691–1695. PubMed

Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–270. PubMed PMC

Margolin D, Kieseier B, Palmer J, Ziemssen T. Alemtuzumab has similar efficacy and safety in active relapsing-remitting multiple sclerosis (RRMS) patients who were treatment-naive or who relapsed on prior therapy (P2.209) Neurology. 2014;82(10 suppl):2, 209.

Arnold DL, Traboulsee A, Cohen JA, et al. Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years (P1100). Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 7–10, 2015; Barcelona, Spain.

Barkhof F, Cohen JA, Coles AJ, et al. Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE-MS I and II extension study. Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 7–10, 2015; Barcelona, Spain.

Fox EJ, Arnold DL, Cohen JA, et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years (P1102). Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 7–10, 2015; Barcelona, Spain.

Havrdova E, Arnold DL, Cohen JA, et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE-MS I extension study (P152). Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 7–10, 2015; Barcelona, Spain.

Traboulsee A, Cohen JA, Coles AJ, et al. Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years (P1103). Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2015; Barcelona, Spain.

Limmroth V, Giovannoni G, Arnold DL, et al. Treatment-naive patients with active RRMS demonstrate durable improvements in relapse and disability following treatment with alemtuzumab: 5-year follow-up of the CARE-MS I Study. Neurology. 2016;86(16 suppl):S51.004.

Fox EJ, Arnold DL, Cohen JA, et al. Durable efficacy in RRMS patients receiving two annual courses of alemtuzumab and no additional treatment for 4 years: pooled analysis of CARE-MS I and II. Neurology. 2016;86(16 suppl):S51.005.

Arroyo Gonzalez R, Kita M, Crayton H, CARE-MS I and II Investigators et al. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler. 2017;23(10):1367–1376. PubMed

Arroyo González R, Moreau T, Hartung HP, et al. Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1 (P1152). Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 7–10, 2015; Barcelona, Spain.

Kita M, Cohen J, Moreau TT, et al. Improvement in disability with alemtuzumab is associated with quality of life improvement over 3 years in patients who relapsed on prior therapy. Neurology. 2015;84(14 suppl):3, 260.

Mayer L, Fox EJ, LaGanke C, et al. Incidence of infusion-associated reactions decreases with subsequent courses of alemtuzumab: 5-year data from the CARE-MS extension study (DX44). Paper presented at: 30th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); June 1–4, 2016; National Harbor, MD, USA.

Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11(1 Suppl):37–42. PubMed

Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7(1):55–63. PubMed

McEwan L, Caon C, Chieffe C, Mayer L, Saldana-King T, Miller CE. Best practices in alemtuzumab administration: practical recommendations for infusion patients with multple sclerosis. J Infus Nurs. 2016;39(2):93–104. PubMed

Caon C, Namey M, Meyer C, et al. Prevention and management of infusion-associated reactions in the comparison of Alemtuzumab and Rebif ® Efficacy in Multiple Sclerosis (CARE-MS) Program. Int J MS Care. 2015;17(4):191–198. PubMed PMC

Wray S, Boyko AN, Braley T, et al. Administration of alemtuzumab on nonconsecutive days does not impact infusion-associated reactions, efficacy, or lymphocyte depletion. Neurology. 2015;84(14 suppl):7, 277.

Jung Henson L, Arnold D, Cohen J, et al. Incidence of infection decreases over time in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis: 4-year follow-up of the CARE-MS Studies. Neurology. 2015;84(14 suppl):7, 265.

Selmaj KW, Habek M, Bass A, et al. Efficacy and safety of alemtuzumab in patients with RRMS is durable over 10 years: follow-up from the CAMMS223 study. Neurology. 2017;88(16 suppl):5, 338.

Holmøy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab a case for better preventive strategies. BMC Neurol. 2017;17(1):65. PubMed PMC

Décard BF, Thöne J, Haghikia A, et al. Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient. Mult Scler. 2017;23(1):123–125. PubMed

Hernandez-Milian A, Payeras-Cifre A. What is new in listeriosis? Biomed Res Int. 2014;2014:358051. PubMed PMC

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler. 2017;23(6):874–876. PubMed

Pfeuffer S, Beuker C, Ruck T, et al. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology. 2016;87(22):2380–2381. PubMed

Sheikh-Taha M, Corman LC. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler. 2017;23(6):872–874. PubMed

Senior PA, Arnold DL, Cohen JA, et al. Incidence and timing of thyroid adverse events in patients with RRMS treated with alemtuzumab through 5 years of the CARE-MS Studies. Neurology. 2016;86(16 suppl):2, 086.

Cuker A, Arnold DL, Cohen JA, et al. Detection and management of immune thrombocytopenia in alemtuzumab-treated patients in the Multiple Sclerosis Clinical Development Program (P590). Paper presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 7–10, 2015; Barcelona, Spain.

Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299–6305. PubMed

Ghodasara RS, Rarick MB, Mosley MC, et al. Alemtuzumab causes significant, transient, post-infusion thrombocytopenia and other non autoimmune cytopenias following initial and subsequent courses. Paper presented at: Consortium of Multiple Sclerosis Centers Annual Meeting; June 1–4 2016; National Harbor, MD, USA.

Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Multiple Scler. 2017 Mar 1; Epub. PubMed

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. PubMed

Wynn D, Arnold DL, Cohen JA, et al. Detection, incidence, and management of glomerulonephritis in the alemtuzumab clinical development program (P597). Paper presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 2–5, 2013; Copenhagen, Denmark.

Haghikia A, Dendrou CA, Schneider R, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol. 2017;16(3):104–106. PubMed

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74(8):961–969. PubMed PMC

Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005;84(2):98–106. PubMed

Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20(2):349–360. PubMed

Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85(11):4254–4257. PubMed

Ting SS, Ziegler JB, Vowels MR. Acquired autoimmune thrombocytopenia post-bone marrow transplantation for severe combined immunodeficiency. Bone Marrow Transplant. 1998;21(8):841–843. PubMed

Miller T, Habek M, Coles AJ, et al. Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy. Paper presented at: Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting; September 10–13, 2014; Boston, MA, USA.

Lecumberri B, Arnold DL, Cohen JA, et al. Detection of thyroid malignancies in alemtuzumab-treated patients in the multiple sclerosis clinical development program. Mult Scler. 2015;21(S11):P1117.

Oh J, Achiron A, Chambers C, et al. Pregnancy outcomes in patients with RRMS who received alemtuzumab in the Clinical Development Program (S24.008) Neurology. 2016;86(16 Suppl):S24.008.

Hassoun L, Eisele J, Thomas K, Ziemssen T. Hands on alemtuzumab experience from clinical practice: whom and how to treat. Multi Scler Demyelinating Disorders. 2016;1(10):1–14.

Rog D, Seferta N, Daniel D, et al. LEMTRADA® (Alemtuzumab) Pregnancy Exposure Registry: study design and enrolment procedures for pregnant women with multiple sclerosis exposed to alemtuzumab. MS Trust 2015 Conference; November 8–10, 2015; Windsor, UK.

Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256(4):554–562. PubMed

Mayer L, Casady L, Clayton G, et al. Management of infusion-associated reactions in alemtuzumab-treated relapsing-remitting multiple sclerosis patients (P880). Paper presented at: Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting; September 10–13, 2014; Boston, MA, USA.

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management